Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study


Inal A., Kos F. T., Algin E., Yildiz R., Berk V., Unek I. T., ...Daha Fazla

JOURNAL OF BUON, cilt.17, sa.1, ss.102-105, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 1
  • Basım Tarihi: 2012
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.102-105
  • Anahtar Kelimeler: cancer, gemcitabine, pancreas, prognosis, SINGLE-AGENT GEMCITABINE, RANDOMIZED PHASE-III, ADENOCARCINOMA, INDEX
  • Gazi Üniversitesi Adresli: Evet

Özet

Purpose: The majority of patients with pancreatic cancer present with advanced disease. Systemic chemotherapy for patients with pancreatic cancer has limited impact on overall survival (OS). Patients eligible for chemotherapy should be selected carefully. The aim of this study was to analyse prognostic factors for OS in advanced pancreatic cancer patients treated with first-line palliative chemotherapy with gemcitabine alone or gemcitabine plus cisplatin.